Our study also showed a trend whereby sIBM patients with anti-NT5c1A positivity are more likely to have higher disease severity (e.g., muscle weakness) compared to those without anti-NT5c1A antibodies, suggesting these antibodies may have a pathogenic role.
1
—
—